Jacobs Levy Equity Management, Inc Aerie Pharmaceuticals Inc Transaction History

Jacobs Levy Equity Management, Inc

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2022 Nov 15, 2022	SELL	$6.37 - $15.23 $6.26 Million - $15 Million	-982,868 Reduced 83.04%	200,808 $3.04 Million
Q2 2022 Aug 15, 2022	BUY	$4.95 - $9.16 $457,276 - $846,191	92,379 Added 8.47%	1,183,676 $8.88 Million
Q1 2022 May 16, 2022	BUY	$5.64 - $9.8 $432,819 - $752,061	76,741 Added 7.56%	1,091,297 $9.93 Million
Q4 2021 Feb 14, 2022	BUY	$7.02 - $13.33 $2.88 Million - $5.46 Million	409,917 Added 67.8%	1,014,556 $7.12 Million
Q3 2021 Nov 15, 2021	BUY	$11.32 - $16.63 $303,455 - $445,800	26,807 Added 4.64%	604,639 $6.89 Million
Q2 2021 Aug 16, 2021	BUY	$15.16 - $18.97 $5.72 Million - $7.16 Million	377,604 Added 188.59%	577,832 $9.25 Million
Q1 2021 May 17, 2021	SELL	$13.12 - $20.9 $4.49 Million - $7.15 Million	-341,947 Reduced 63.07%	200,228 $3.58 Million
Q4 2020 Feb 16, 2021	BUY	$9.12 - $14.49 $3.57 Million - $5.67 Million	391,385 Added 259.56%	542,175 $7.33 Million
Q3 2020 Nov 16, 2020	BUY	$10.46 - $14.46 $1.58 Million - $2.18 Million	150,790 New	150,790 $1.78 Million

2.4M

Ticker AERI
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—Specialty & Generic
Shares Outstandng 49,390,500
Description
Aerie Pharmaceuticals, Inc., a pharmaceutical company, focuses on the discovery, development, and commercialization of ophthalmic therapies for open-angle glaucoma, dry eye, diabetic macular edema, and wet age-related macular degeneration in the United States. Its products include Rhopressa, a once-daily eye drop to reduce elevated intraocular p...

Get notified when there are updates to the investment portfolio of Jacobs Levy Equity Management, Inc, based on Form 13F filings with the SEC.

Stay updated on Jacobs Levy Equity Management, Inc with notifications on news.